Holen Sie sich die Stockscreener-App
34.06
0.89%
0.30
Handel nachbörslich:
35.60
1.54
+4.52%
Schlusskurs vom Vortag:
$33.76
Offen:
$33.84
24-Stunden-Volumen:
7.63M
Relative Volume:
0.91
Marktkapitalisierung:
$13.11B
Einnahmen:
$5.06B
Nettoeinkommen (Verlust:
$-2.22B
KGV:
-5.8522
EPS:
-5.82
Netto-Cashflow:
$-3.96B
1W Leistung:
-19.38%
1M Leistung:
-16.44%
6M Leistung:
-72.54%
1J Leistung:
-66.06%
1-Tages-Spanne:
$33.60
$34.79
1-Wochen-Bereich:
$31.94
$35.68
52-Wochen-Spanne:
$31.94
$170.47
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Vergleichen Sie MRNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
34.06 | 13.11B | 5.06B | -2.22B | -3.96B | -5.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
Moderna to receive $590m from HHS for mRNA influenza vaccines - Pharmaceutical Technology
Under-Pressure Moderna Banks $590m To Speed Up Bird Flu Vaccine - News & Insights
Moderna Awarded $590 Million To Develop Bird Flu Vaccine - Baystreet.ca
Moderna Secures $590M Funding From U.S. Government for Bird Flu Jab - Yahoo Finance
Dept. of Health Services awards Moderna $590 million to develop flu vaccines, bird flu vaccine - WSB Radio
Moderna wins US govt award for mRNA vaccine development - The Pharma Letter
Why Moderna, Inc. (MRNA) Crashed Last Week - Insider Monkey
Jim Cramer Says Moderna, Inc. (MRNA) Has Been ‘One Of The Biggest Disappointments Of The Year’ - Insider Monkey
Moderna Stock: Opportunity In Avian Flu, Merck Partnership (NASDAQ:MRNA) - Seeking Alpha
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? - Benzinga
Is Moderna Stock a Buy? - sharewise
If I Could Buy Only 1 ETF in 2025, This Would Be It - The Motley Fool
Avanza Fonder AB Takes $1.39 Million Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Jim Cramer Says Moderna, Inc. (MRNA) Is ‘So Luckless’ - Insider Monkey
U.S. pays $590 million to Moderna to speed up development of bird flu vaccine - NPR
Moderna Boosted by $590 Million Grant for Pandemic Influenza VaccinesNews and Statistics - IndexBox, Inc.
Moderna awarded $590M to help accelerate development of mRNA-based bird flu vaccine: HHS - weisradio.com
Moderna awarded $590M to help accelerate development of mRNA-based bird flu vaccine - WBAL Radio
Moderna Inc (MRNA) Stock Price, Trades & News - GuruFocus.com
FY2024 EPS Estimates for Moderna Increased by William Blair - MarketBeat
Moderna’s meant to be a red-hot growth stock. What on earth’s gone wrong? - Yahoo Finance UK
Moderna Gets $590M to Speed Bird Flu Vaccine - Newsmax
Investors Purchase Large Volume of Moderna Put Options (NASDAQ:MRNA) - MarketBeat
HHS invests nearly $600 million in Moderna’s bird flu vaccine development - KoamNewsNow.com
Moderna Gets $590 Million in Federal Funding for Bird Flu Vaccine - The Wall Street Journal
Stocks to Watch: Walgreens Boots Alliance, Moderna - MarketWatch
US awards Moderna $590 million for bird flu vaccine development - Reuters
Moderna Gets Additional US Vaccine Funds Amid Bird Flu Outbreak - Bloomberg
U.S. awards Moderna US$590-million for bird flu vaccine development - The Globe and Mail
Moderna gets $590M HHS contract to develop mRNA pandemic flu vaccines (MRNA:NASDAQ) - Seeking Alpha
Moderna Gets $590 Million From U.S. to Accelerate Bird Flu Vaccine - Barron's
Moderna Announces Updates on Pandemic Influenza Program - Yahoo Finance
Moderna stock surges on bird flu vaccine funding By Investing.com - Investing.com UK
How to Play Moderna Stock After the Recent Sales Guidance Cut - Yahoo Finance
Moderna surprises the Street by predicting a bigger-than-expected sales drop - MSN
FY2024 Earnings Estimate for Moderna Issued By William Blair - MarketBeat
Leerink Partners Cuts Moderna (NASDAQ:MRNA) Price Target to $27.00 - MarketBeat
The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK - Yahoo Finance
Moderna Dropped by 20% This Week -- Is It a Smart Buy Right Now? - sharewise
Why Moderna (MRNA) Stock is Moving Today - GuruFocus.com
CDC upgrades its advisory on bird flu. Will Moderna’s stock get a boost? - MarketWatch
Is Moderna a Bad-News Buy for 2025? - sharewise
A Closer Look at Moderna's Options Market Dynamics - Benzinga
FY2024 EPS Estimates for Moderna Cut by Analyst - MarketBeat
Down 79%, Is Moderna Stock a Bad-News Buy on the Dip? - AOL
Analyst recommendations: Datadog, Estee Lauder, Netflix, Moderna, EasyJet... - Marketscreener.com
Analysts Issue Forecasts for Moderna FY2029 Earnings - MarketBeat
Moderna stock plunges 18% after company lowers 2025 sales forecast by $1 billion - MSN
Is Moderna (MRNA) the Stock That Will Go to the Moon According to Reddit? - Yahoo Finance
Healthcare: Sector Looks Undervalued with Pullback After US Election and Obesity Data - Morningstar
Moderna Stock: A Deep Dive Into Analyst Perspectives (10 Ratings) - Benzinga
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
4.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):